Safety and Effectiveness of Long Paclitaxel-Eluting Stents in patients with de novo coronary disease in Shaheed Rajaee Cardiovascular Medical and Research Center

A great revolution happened in coronary intervention after the invention of drug eluting stents (DES). Different types of DES have been made. Stents with biocompatible polysulfone polymer and paclitaxel drug is newly introduced. In this study we aimed to evaluate the efficacy of this new drug eluting stent. All consecutive patients underwent coronary angioplasty with paclitaxel eluting stents from January to March 2009 were enrolled. Data was collected in answer sheath and analyzed with SPSS 18. One hundred patients were included in this study, with mean age of 55.21±10.00. Most of the patients were male (70%). The most common risk factor was hyperlipidemia (47%). Most of the lesions undergone angioplasty was in B2/C ACC/AHA class, and LAD was the most common vessel. In this study the rate of technical and procedural success was 100%. There was not any early or late thrombosis, and death, myocardial infarction and stroke (major adverse cardiovascular events, MACE) was similar to other drug eluting stents. Stenting with paclitaxel eluting stents is safe. Regarding its biocompatible polymer it doesn''t have any added hazard compared to bare metal stents. Further studies needed for other aspects